Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs

Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 50% of the patients experience resistance within two years of treatment underscoring the need to get better insight into the mechanisms conferring imatinib resistance. Here the microRNA and mRNA expression pr...

Full description

Bibliographic Details
Main Authors: Azadeh Amirnasr, Caroline M.M. Gits, Patricia F. van Kuijk, Marcel Smid, Anne L.M. Vriends, Piotr Rutkowski, Raf Sciot, Patrick Schöffski, Maria Debiec-Rychter, Stefan Sleijfer, Erik A. C. Wiemer
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
GIST
miRNA
mRNA expression
imatinib
drug resistance
gene networks
IPA pathway analysis
Online Access:https://www.mdpi.com/2072-6694/11/6/882

Internet

https://www.mdpi.com/2072-6694/11/6/882

Similar Items